GSK-209762/149 (MeMuRu-149)

Study Sponsor: GSK

Study Title

Phase IV, single-blind, randomised, multicenter study to evaluate immediate post-vaccination pain, reactogenicity and tolerance of GSK Bio’s Measles-Mumps-Rubella vaccine (Priorix) administered as a second dose compared to Aventis-Pasteur-MSDs Measles-Mumps-Rubella vaccine (ROR Vax)

Medicine or Vaccine (generic name)

Measles, Mumps, Rubella Vaccine

Sponsor Identification Number

209762/149 (MeMuRu-149)

Trial Registry Identification Number(#'s)

Medical Condition

Measles; Mumps; Rubella

Phase

Phase 4

Link to GSK Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=209762/149

Link to study details on ClinicalTrials.gov (if available)

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A clinical study report and a protocol are not available for this study because English language versions were not created. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.

Date Added to this Site

June 2015